MYD88 (L265P) mutation is associated with an unfavourable outcome of primary central nervous system lymphoma-Reference-Cited by-同舟云学术

MYD88 (L265P) mutation is associated with an unfavourable outcome of primary central nervous system lymphoma

Published:2016-05-10 Issue:3 Volume:177 Page:492-494
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Hattori Keiichiro¹,Sakata-Yanagimoto Mamiko¹,Okoshi Yasushi²³,Goshima Yuki⁴,Yanagimoto Shintaro⁵,Nakamoto-Matsubara Rie¹,Sato Taiki⁶,Noguchi Masayuki⁶,Takano Shingo⁷,Ishikawa Eichi⁷,Yamamoto Tetsuya⁷,Matsumura Akira⁷,Chiba Shigeru¹

Affiliation:

1. Department of Clinical and Experimental Haematology; Institute of Clinical Medicine; University of Tsukuba; Tsukuba Japan

2. Ibaraki Clinical Education and Training Centre; University of Tsukuba Hospital; Tsukuba Ibaraki Japan

3. Department of Haematology; Ibaraki Prefectural Central Hospital; Tsukuba Ibaraki Japan

4. School of Medicine; University of Tsukuba; Tsukuba Japan

5. Division for Health Service Promotion; The University of Tokyo; Bunkyo-ku, Tokyo Japan

6. Department of Pathology; Institute of Clinical Medicine; University of Tsukuba; Tsukuba Japan

7. Department of Neurosurgery; Institute of Clinical Medicine; University of Tsukuba; Tsukuba Japan

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.14080/fullpdf

Reference10 articles.

1. Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model;Abrey;Journal of Clinical Oncology,2006

2. Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse;Bernard;Blood,2015

3. Genome-wide analysis uncovers novel recurrent alterations in primary central nervous system lymphomas;Braggio;Clinical Cancer Research,2015

4. MYD88 (L265P) mutation is an independent prognostic factor for outcome in patients with diffuse large B-cell lymphoma;Fernandez-Rodriguez;Leukemia,2014

5. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry;Pastore;The Lancet Oncology,2015

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bibliometric analysis of emerging trend and top 100 most cited articles in primary central nervous system lymphoma;2024-07-17

2. Comparative Study on the Clinicopathologic and Molecular Characteristics of Primary and Secondary Diffuse Large B-cell Lymphoma in the Central Nervous System;Anticancer Research;2024-06-26

3. The Molecular Landscape of Primary CNS Lymphomas (PCNSLs) in Children and Young Adults;Cancers;2024-04-29

4. Genomic Profiling of Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System Suggests Novel Potential Therapeutic Targets;Modern Pathology;2023-12

5. Extranodal lymphoma: pathogenesis, diagnosis and treatment;Molecular Biomedicine;2023-09-18